Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Perindopril 8 mg vs Prestarium A 10 mg in Healthy Volunteers
NCT06213610Phase 1Recruiting
- Sponsor
- Pharmtechnology
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perindopril in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum observed plasma concentration of perindopril, Area under the plasma concentration-time curve from time zero to 72 hours for perindopril and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
perindopril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06213610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213610.